The modest insider buy is a minor positive signal but not sufficient to change the risk/reward profile. Monitor for further insider purchases and upcoming Phase 3 trial initiation for urcosimod. The stock remains a high-risk clinical-stage biotech with no revenue.
Price Chart
Executive Summary
OKYO Pharma Chairman Gabriele Cerrone purchased 22,500 ordinary shares at $1.45 per share, increasing his total holdings to 10,873,916 shares (20.55% of issued share capital). The purchase is modest ($32,625) relative to the $49M market cap and represents a minor insider vote of confidence. The company also reiterated plans to initiate a Phase 3 trial for urcosimod in H2 2026, but the filing's primary substance is the insider buy.
Key Facts
- Chairman Gabriele Cerrone purchased 22,500 ordinary shares via Panetta Partners Ltd at $1.45 per share.
- Total beneficial ownership increased to 10,873,916 shares, representing 20.55% of issued share capital.
- Purchase value is approximately $32,625, a small fraction of the $49M market cap.
- Company plans to initiate a global Phase 3 pivotal trial for urcosimod in H2 2026.
Financial Impact
Insider purchase of $32,625 (0.066% of market cap) — no material financial impact.
Risk Factors
- Clinical trial failure for urcosimod in neuropathic corneal pain.
- Dilution risk from future equity offerings (shelf registration effective).
- No approved products or revenue streams.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-034201 |
| Exhibit: ex99-1.htm | 0001493152-26-034201 |
| Document: 0001493152-26-034201-index-headers.html | 0001493152-26-034201 |
| Document: 0001493152-26-034201-index.html | 0001493152-26-034201 |
| Document: 0001493152-26-034201.txt | 0001493152-26-034201 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.44 (−1.37%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.44 (−1.37%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.44 (+5.88%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.44 (−5.88%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.44 (−8.28%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.44 (−12.20%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.44 (−12.20%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers